This roundtable series provides context on the growing number of options for patients with non–small cell lung cancer and KRAS G12C mutations, as discussed by key opinion leaders and participants at virtual live events.
Adagrasib Shows Efficacy and Tolerability in KRAS G12C–Mutated NSCLC
Shirish M. Gadgeel, MD, MBBS, discusses the results of the KRYSTAL-1 trial trial of adagrasib in patients with KRAS-positive non–small cell lung cancer.
Physicians Discuss Rebiopsy Options Before Second-Line NSCLC Therapy
During a Targeted Oncology™ Case-Based Roundtable™ event, Anne S. Tsao discussed with participants
2 Clarke Drive Cranbury, NJ 08512